SEC Form 3 filed by new insider Bjork Elisabeth
$PHVS
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 15,167(1) | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | 03/03/2027(2) | 03/03/2036 | Common Stock | 16,500 | $28 | D | |
| Stock Option (Right to Buy) | 03/12/2026(2) | 03/12/2035 | Common Stock | 15,000 | $16.05 | D | |
| Stock Option (Right to Buy) | 04/11/2026(2) | 04/11/2034 | Common Stock | 14,000 | $22.31 | D | |
| Stock Option (Right to Buy) | (3) | 04/06/2033 | Common Stock | 21,000 | $8.05 | D | |
| Stock Option (Right to Buy) | (4) | 04/01/2032 | Common Stock | 17,500 | $18.14 | D | |
| Stock Option (Right to Buy) | (5) | 01/01/2032 | Common Stock | 35,000 | $14.39 | D | |
| Explanation of Responses: |
| 1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027. |
| 2. 100% of the option vest on the 12-month anniversary. |
| 3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. |
| 4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. |
| 5. 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. |
| /s/ Marnus Nel, Attorney-in-Fact for Elisabeth Bjork | 03/18/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||